knowledge -WSS

knowledge

author：entertainment 2025-08-19 06:17:25 - browse：93

Rising drug prices —Medicare coverage from STAT — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start. APStock

WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start.

Medicare released an initial outline of how the program will work in March. Some parts, including the outline of how drugs would be selected for the negotiation process, were immediately final. The agency asked drug companies, patients, and other affected parties to weigh in on other parts about how the process would proceed, what factors would be considered, and how drugmakers would be held accountable.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care

Please enter a valid email address. Privacy Policy

The negotiation process was created last August in Democrats’ drug pricing reform law, and Medicare is supposed to select the first 10 drugs that will be subject to negotiation by Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： JPM 2024: Nvidia claims we're in biological revolution. Are we?

WSS

Health and fitness trackers are measuring the wrong things

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Covid isolation guidance eased by the CDC

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Flu vaccine offering decent levels of protection this winter, new data show

hotspot

knowledge

Sign up for D.C. Diagnosis

knowledge

Sports medicine is finally prioritizing gender equality

Flu vaccine offering decent levels of protection this winter, new data show

How one medical school became remarkably diverse

ALS groups 'won't be played again' by the FDA, drug sponsors

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FogPharma raises $145 million in rare Series E round

The high cost of giving birth even with insurance

Designating disabled people as health disparity population is crucial

Medicare details structure of new drug price negotiation program

A Q&A with Aletha Maybank, AMA’s chief health equity officer

hotspot

Covid isolation guidance eased by the CDC

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

International team creates first chimeric human

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

knowledge

hotspot

explore

Wikipedia